Mundipharma
Andrew Cochran is a seasoned professional in commercial and corporate real estate, currently serving as Director Global Real Estate at Mundipharma since February 2024. Prior to this role, Andrew held multiple senior positions at Thomson Reuters from May 2016 to February 2024, including Senior Director of Real Estate and Facility Management for EMEA and Head of Portfolio Management for EMEA, focusing on the strategic execution of the real estate portfolio. Experience at Colliers-International spanned from January 2008 to May 2016, where roles included Director EMEA Corporate Solutions and Associate Director, providing services throughout Europe and MEA regions. Earlier career highlights include a tenure at Cushman & Wakefield as Senior Surveyor for Corporate Solutions, working with Nokia, and positions at Eric Young & Co in retail leasing across Scotland, along with site acquisition work for telecom providers at Stappard Howes. Andrew holds a Bachelor of Land Economy from the University of Aberdeen, an MRICS designation, and a CoreNet Master of Corporate Real Estate.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.